Sharp Clinical Services
Sharp Packaging Services works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry.
We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands.
We’ve built an exceptional global reputation for the design, serialisation and production of innovative, cost-effective compliance packaging for even the most complex products.
Our extensive range includes blister packs, bottles, pouches and stick packs, but our expertise goes far beyond, enabling us to support your product through every stage of design, development, manufacture and delivery.
Our clinical services division is one of the world’s leading providers of innovative clinical supply chain services, with a talented and highly experienced team that can handle every aspect of your supply chain. Our work spans everything from drug development and manufacturing to clinical supplies packaging, labelling, distribution, Qualified Person auditing and comparator sourcing.
Dr Marius OpreanBusiness Development Manager
SiSaf is a Specialty Biopharmaceutical company with a unique patented next-generation Bio-adoptive silicon technology that can elegantly re-invent and solve even the most complex drug and bio-availability challenges.
Dr Michael WelshChief Scientific Officer
Strategy in Life Sciences
Strategy in Life Sciences (SiLS) is a strategy consulting firm focused on the needs of the life sciences sector. We work with organisations to improve their performance, drive high quality decision making and develop winning strategies.
We work on issues from R&D portfolio management to commercial strategy, underpinned by our knowledge of the industry, strategy development and underlying science. Our experience includes working with companies and organisations across the world.
Synpromics is a Synthetic Biology company with IP and know-how in the design of Synthetic Promoters.
Our synthetic promoters enable the controlled expression of genes at a specific place, in a specific environment, at a specific time, or in response to a specific biological condition.
We provide solutions to our customers across multiple fields of use. Such as biotherapeutic protein production; targeted gene therapies and DNA vaccines; enhanced functionality of cell therapies; as well as research tools.
Our clients use our promoters in their applications and products. As each promoter is IP protected it allows us to generate revenue through license agreements that provide up-front and milestone payments during our clients product development, and attractive royalties on our clients product sales.
Mr Nick HigginsBusiness Development Director
An Australian headquartered biotechnology company with labs/offices in Melbourne (Australia), Cambridge (UK), San Francisco (USA) and China (Shanghai & Suzhou), SYNthesis Research has established a number of R&D collaborations which have generated novel IP which is now available for partnering. SYNthesis Research's sister company, SYNthesis med chem, is a chemistry-focussed contract research organisation that carries out custom synthesis and medicinal chemistry projects.
Professor Andrew WilksFounder & Chairman
Mr Simon BuryHead of Business Development
Tecrea Ltd is a UK based Biotechnology Company focused on nanotechnology as a means of creating novel drug formulations to treat serious medical conditions in human and animal health. Our Nanocin™ nanotechnology platform has already been partnered in both human and animal health. Commercial traction has been achieved with sales and out-licensing to bioprocessing and pharmaceutical companies, with one of our partners entering phase II clinical development early in 2017.
The Research Network
TRN are an integrated team of scientific experts who provide Pharmaceutical R&D scientific consultancy, project management, outsourcing and due diligence services. Our experienced team has in depth expertise across the key drug discovery and development disciplines covering both small molecule and biotherapeutics.
TRN also collaborate with Universities and research organisations to progress promising drug discovery projects from lead identification through early clinical development. We partner with Principal Investigators and Technology Transfer groups to secure funding, provide strategic guidance and practical support to access and manage available technologies and resources worldwide. Much of this work is conducted at risk. Areas of focus are acute care, antibiotics, antivirals, neurodegeneration and CVMD.
TRN are currently working in collaboration with the University of Tennessee and the MRCT to enable the development of EmstoPA, a humanised antibody fragment for the treatment of bleeding complications in patients who have received the clot buster tPA, for the treatment of stroke or pulmonary embolism. Currently no specific tPA reversal agents are in development. The team are seeking investors to help fund the development of this exciting and innovative product. Two additional drug repurposing collaborations are in early development in the acute care arena.
Dr Charles PhillipsNetwork Partner, Regulatory Team Lead
Therakind, a, private pharmaceutical company, is focused on developing safe, effective, authorised speciality medicines. To date, two paediatric products have been successfully developed and commercialised and a portfolio of further products are under development in late stage development Therakind is developing a portfolio of further products. We have an earlier stage diabetic nasal product for treatment of hypoglycaemia and a pipeline of further products.
Therakind operates with several business models to generate a platform of products generating royalties and also provides consultancy in pharmaceutical development.
Touchlight’s in vitro enzymatic DNA amplification platform addresses every major limitation of pDNA fermentation. Touchlight’s platform has improved yield, speed & fidelity, no antibiotic resistance & the ability to amplify complex secondary structures.
Miss Sarah MilsomGroup Business Development Manager
Ubiquigent provides its partners with unparalleled access to the technologies, skills and expertise required to support drug discovery in the ubiquitin field. The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity.
To support the exploitation of the ubiquitin system Ubiquigent has recently launched the first novel compound library designed to target Deubiquitylase (DUB) enzymes (DUBtarget-001), with further compound libraries to follow. Ubiquigent also provides access to specialist drug discovery services, high quality research tools and chemistry to support groups that are either already active in or wish to enter this exciting new field.
The ubiquitin system is based on the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls). Ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar if not greater potential for clinical utility.
Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery. Ubiquigent benefits from high calibre backing including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.